Literature DB >> 19443368

Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer.

Frank Chih-Kang Chen1, Guelten Oskay-Ozcelik, Kai J Bühling, Uta Köpstein, Monika Mentze, Werner Lichtenegger, Jalid Sehouli.   

Abstract

UNLABELLED: The aim of this study was to investigate the influence of sex hormone levels on tumor biology and patients' outcome in ovarian cancer. PATIENTS AND METHODS: One hundred and six patients with ovarian cancer were enrolled into this prospective study. Serum and ascites samples were obtained intraoperatively. Concentrations of estradiol, FSH, LH and prolactin were measured and correlated with parameters of tumor biology, such as FIGO stage, tumor spread and postoperative tumor residual mass. Patients with primary ovarian cancer were compared to patients with recurrent disease. Influence factors on progression-free survival and overall survival were analyzed using the Kaplan-Meyer method.
RESULTS: Serum FSH concentrations were significantly higher and estradiol concentrations in ascites were significantly lower in patients with recurrent disease. According the multivariate analysis, only FSH level in ascites was seen to be an independent prognostic factor for patients' survival.
CONCLUSION: High level of FSH in the ascites provides prognostic information in patients with ovarian cancer and is inversely correlated with patients' survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443368

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Authors:  Alfredo Perales-Puchalt; Nikolaos Svoronos; Melanie R Rutkowski; Michael J Allegrezza; Amelia J Tesone; Kyle K Payne; Jayamanna Wickramasinghe; Jenny M Nguyen; Shane W O'Brien; Kiranmai Gumireddy; Qihong Huang; Mark G Cadungog; Denise C Connolly; Julia Tchou; Tyler J Curiel; Jose R Conejo-Garcia
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

2.  Role of sex hormones in the modulation of cholangiocyte function.

Authors:  Romina Mancinelli; Paolo Onori; Sharon Demorrow; Heather Francis; Shannon Glaser; Antonio Franchitto; Guido Carpino; Gianfranco Alpini; Eugenio Gaudio
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

3.  FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.

Authors:  Xiang Tao; Naiqing Zhao; Hongyan Jin; Zhenbo Zhang; Yintao Liu; Jian Wu; Robert C Bast; Yinhua Yu; Youji Feng
Journal:  Endocr Relat Cancer       Date:  2013-05-30       Impact factor: 5.678

4.  Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.

Authors:  Miriam Lenhard; Alexandra Tsvilina; Lan Schumacher; Markus Kupka; Nina Ditsch; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-01-03       Impact factor: 4.430

5.  Establishment of A Reversibly Inducible Porcine Granulosa Cell Line.

Authors:  Yinshan Bai; Cui Zhu; Meiying Feng; Bo Pan; Shouquan Zhang; Xiaoshu Zhan; Huifang Chen; Bingyun Wang; Julang Li
Journal:  Cells       Date:  2020-01-08       Impact factor: 6.600

6.  Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.

Authors:  Miriam Lenhard; Lennerová Tereza; Sabine Heublein; Nina Ditsch; Isabelle Himsl; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-11-24       Impact factor: 4.430

7.  Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer.

Authors:  Jun Zhou; Yiding Chen; Yiting Huang; Jinpei Long; Fang Wan; Suzhan Zhang
Journal:  Oncol Lett       Date:  2013-08-07       Impact factor: 2.967

8.  Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.

Authors:  Yuka Hattori; Shizuka Yamada; Makoto Yamamoto; Makoto Orisaka; Tetsuya Mizutani; Yoshio Yoshida
Journal:  J Ovarian Res       Date:  2015-11-14       Impact factor: 4.234

9.  Follicle-Stimulating Hormone Is an Autocrine Regulator of the Ovarian Cancer Metastatic Niche Through Notch Signaling.

Authors:  Sakshi Gera; Sandeep Kumar S; Shalini N Swamy; Rahul Bhagat; Annapurna Vadaparty; Ramesh Gawari; Ramray Bhat; Rajan R Dighe
Journal:  J Endocr Soc       Date:  2018-12-12

10.  DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers.

Authors:  Stella D'Oronzo; Erica Silvestris; Domenica Lovero; Paola Cafforio; Loren Duda; Gennaro Cormio; Angelo Paradiso; Raffaele Palmirotta; Franco Silvestris
Journal:  Int J Mol Sci       Date:  2020-08-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.